Day: March 12, 2026

The FDA’s recent release of two guidance documents for developing biosimilars signals a critical shift toward regulatory efficiency. For senior management and regulatory affairs leads, these documents clarify the Agency’s move to reduce redundant clinical testing and streamline the use of global comparator data. Understanding these nuances is essential for optimizing development timelines and capital … Read more

Following the issuance of a Form FDA 483, the window for regulatory advocacy is brief and high-stakes, necessitating a response that serves as a cornerstone for future enforcement decisions. While the industry has long relied on historical precedent and unofficial best practices, the March 2026 draft guidance finally formalizes the Agency’s expectations for post-inspection communication. … Read more